FDA warns antiviral Hepatitis C drug users risk reactivation

Ryan Maass
WASHINGTON, Oct. 5 (UPI) — According to FDA officials, patients using direct-acting antiviral medicines for hepatitis C may end up reactivating the disease in the form of hepatitis B. …read more

Source:: National and World Stories


You must be logged in to post a comment Login